US 10912751
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted A61KA61K31/194A61K31/20
Quick answer
US patent 10912751 (Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease) held by Esperion Therapeutics, Inc. expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Esperion Therapeutics, Inc.
- Grant date
- Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/194, A61K31/20, A61K31/397, A61P